Adipoimmune

Adipoimmune is a biotechnology company focused on developing novel therapeutics for metabolic and autoimmune diseases, with a primary emphasis on Type 1 Diabetes. The company leverages research into the crosstalk between adipose tissue and the immune system to identify new drug targets, a field known as immunometabolism. By modulating these pathways, Adipoimmune aims to preserve pancreatic beta-cell function and improve overall metabolic health. Their approach represents a shift from traditional insulin-centric treatments toward addressing the underlying inflammatory and metabolic drivers of disease. The company is a spin-out from the Indiana University School of Medicine and is headquartered in Indianapolis.